2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
206
NIH
84
INDUSTRY
32
NETWORK
27
FED
3
INDIV
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma
1
Interventions
Proflavine
9
pembrolizumab
2
Tacrolimus
2
Pyridostigmine Bromide
2
Prednisone
2
Microbial Collagenase
2
sargramostim
1
plerixafor
1
pegfilgrastim
1
olaparib
1
nilotinib
1
macimorelin
1
keyhole-limpet hemocyanin
1
ethyl pyruvate
1
compound W
1
blinatumomab
1
Watchful Waiting
1
Uracil
1
Tegafur
1
Surgical Procedures, Operative
1
Steroids
1
Sodium Chloride
1
Sirolimus
1
Salicylates
1
Peptides
1
PM 01183
1
Mycophenolic Acid
1
Monatide (IMS 3015)
1
Mifepristone
1
Methylprednisolone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDIV
×
sargramostim
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled